Although many studies of long COVID-19 were reported, there was a lack of systematic
research which assessed the differences of long COVID-19 in regard to what unique SARS …

Predictions for a near end of the pandemic by the World Health Organization should be
interpreted with caution. Current evidence indicates that the efficacy of a fourth dose of …

Real-world data on the effectiveness of COVID-19 vaccines against the Omicron variant (B.
1.1. 529) is limited. This systematic review aimed to investigate the real-world effectiveness …

Background To date, more than 761 million confirmed SARS-CoV-2 infections have been
recorded globally, and more than half of all children are estimated to be seropositive …

In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the US, Chile,
and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50 …

Emerging in November 2021, the SARS-CoV-2 Omicron variant of concern exhibited
marked immune evasion resulting in reduced vaccine effectiveness against SARS-CoV-2 …

The epidemiological situation of SARS‐CoV‐2 in humans and animals is continually
evolving. To date, animal species known to transmit SARS‐CoV‐2 are American mink …

Background MERS-CoV is a respiratory pathogen with a case-fatality rate of 36%, and for
which no vaccines are currently licensed. MVA-MERS-S is a candidate vaccine based on …

For SARS-CoV-2 mutants, the effectiveness of the COVID-19 vaccines is still controversial.
In this study, we aimed to investigate the clinical characteristics of Omicron-infected patients …

Objectives The rapid spread of the SARS-CoV-2 Omicron variant has raised concerns
regarding waning vaccine-induced immunity and durability. We evaluated protection of the …